ArticleFrontiers in oncology2026
Long-term prognostic comparison of surgery followed by adjuvant chemoradiotherapy versus definitive chemoradiotherapy in T4N0-3M0 esophageal squamous cell carcinoma: a single-center retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This large retrospective study aimed to compare the long-term survival outcomes of esophageal squamous cell carcinoma (ESCC) patients with stage T4N0-3M0 treated with surgery followed by adjuvant chemoradiotherapy (S+CRT) versus definitive chemoradiotherapy (dCRT). Methods: Patients with T4N0-3M0 ESCC who received S+CRT or dCRT at our institution between January 2011 and December 2018 were included in the study. Results: A total of 490 patients with stage T4N0-3M0 ESCC met the enrollment criteria, with 108 in the S+CRT group and 382 in the dCRT group. Overall survival (OS) and progression-free survival (PFS) were significantly better in S+CRT group compared to the dCRT group (P = 0.000, 0.003). After propensity score matching (PSM) analysis, 138 patients in the dCRT group and 81 patients in the S+CRT group were successfully matched. OS and PFS were again significantly better in the S+CRT group compared to the dCRT group (P = 0.002, 0.019). Conclusions: S+CRT is more likely to improve the overall prognosis of patients with T4N0-3M0 ESCC compared to dCRT. Treatment plan should be made based on a thorough consideration of both the patient's condition and tumor characteristics, leading to individualized decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.